We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Medical

Inspira Pharmaceuticals

Status: Active

Apr 22nd 2021 - May 22nd 2021

7 days left

Inspira Pharmaceuticals (IP) is forming a possible new therapy for COVID-19. IP asserts that its in-lab plant-based molecular formulation has killed over 95% of the SARS-CoV-2 virus. The company aims to understand whether a COVID-19 patient can safely inhale the formulation directly into their lungs as an effective treatment. IP has secured cornerstone investment from biotech angel investors and a Singaporean Venture Capitalist (VC) for its formula. IP argues that its technology has the potential for addressing other respiratory infections such as cystic fibrosis, influenza and the common cold in the coming months. The company will use the investment to develop an effective new drug, which will include further laboratory analysis, safety testing, and preparation for human trials.

read more read less
  • £347,176
    pledged
  • 99%
    of goal

    £350,000
    target

    £7,570,500
    pre-money valuation

    4.42%
    equity available

    617
    investors

    £563
    pledge per investor

    13045376
    company number

    Active
    company status

    26/11/2020
    incorporated 6 months

    £0.15
    share price

    Previous Funding rounds
    22 Apr 21 Crowdcube £347,176 / 99%
    News

0 comments

Log in to comment


Funding progress



  • £347,176
    pledged
  • 99%
    of goal

    £350,000
    target

    £7,570,500
    pre-money valuation

    4.42%
    equity available

    617
    investors

    £563
    pledge per investor

    13045376
    company number

    Active
    company status

    26/11/2020
    incorporated 6 months

    £0.15
    share price

    Previous Funding rounds
    22 Apr 21 Crowdcube £347,176 / 99%
    News
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph